IVERIC bio (Ophthotech) Priced, Nasdaq: ISEE
Late-stage biotech developing novel therapeutics for eye diseases.
Industry: Health Care
First Day Return: +19.5%
ISEE
Late-stage biotech developing novel therapeutics for eye diseases.
| IPO Data | |
|---|---|
| IPO Date | 09/24/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $167 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New York, NY, United States |
| Founded | 2007 |
| Employees at IPO | 22 |
| Website www.ophthotech.com | |
IPO News for IVERIC bio (Ophthotech)
IVERIC bio (Ophthotech) (ISEE) Performance
